辅助舒尼替尼治疗后复发肾细胞癌系统靶向治疗结局
多机构回顾性研究评估辅助舒尼替尼失败后复发肾细胞癌患者再挑战舒尼替尼或其他靶向治疗的疗效与耐受性。25例患者接受一线系统靶向治疗,中位无进展生存期12.0个月(95%CI 5.78-18.2),客观缓解率20.5%,中位总生存期29.1个月(95%CI 16.4-41.8)。再挑战舒尼替尼或其他系统治疗仍为可行选择,可提供额外临床获益。
要点
- 辅助舒尼替尼失败后复发RCC,再挑战靶向治疗中位PFS 12.0个月
- 客观缓解率20.5%,中位OS 29.1个月
- 不同治疗间及是否再挑战舒尼替尼的PFS无统计学差异
核心结论
- 辅助舒尼替尼失败后复发晚期或转移性RCC,再挑战舒尼替尼或其他系统靶向治疗仍为可行选择,在PFS和OS方面提供额外临床获益。
研究设计与样本
- 多机构回顾性研究,纳入辅助舒尼替尼治疗后复发的RCC患者,再挑战舒尼替尼或其他系统靶向治疗作为一线方案。
- 共记录34例复发患者,其中25例接受系统靶向治疗;25例中73.5%为男性。
主要发现
- 25例接受系统靶向治疗的患者中,65%接受抗VEGF通路靶向治疗(包括舒尼替尼),21.7%接受mTOR抑制剂,13%接受免疫治疗。
- 中位随访23.5个月时,25例中24例在一线系统治疗中进展。
- 中位PFS为12.0个月(95%CI 5.78-18.2),不同治疗间及舒尼替尼再挑战间PFS无统计学差异。
- 辅助舒尼替尼结束后≤6个月或>6个月复发者PFS无统计学差异;ORR为20.5%,中位OS为29.1个月(95%CI 16.4-41.8)。
关键数值与推荐
- 复发距诊断中位时间20.3个月(四分位距5.2-20.4),距辅助舒尼替尼结束中位时间7.5个月(四分位距1.0-8.5)。
- 主要终点为PFS,次要终点为ORR和OS。
临床怎么用
- 辅助舒尼替尼治疗后复发的晚期RCC患者,可考虑再挑战舒尼替尼或其他系统靶向治疗作为一线选择。
- 治疗决策时无需因辅助治疗结束至复发时间≤6或>6个月而区别选择再挑战策略。
局限性
- 回顾性研究,样本量小(25例接受系统治疗),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and tolerability of rechallenge with sunitinib and other targeted therapies (TTs) in patitents with relapsed recurrent renal cell carcinoma (RCC) in the advanced setting. METHODS: In this multi-institutional retrospective study, patients with relapsed RCC were rechallenged with sunitinib or other systemic TTs as a first-line therapeutic approach after failed adjuvant sunitinib treatment. Patient characteristics, treatments and clinical outcomes were recorded. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR) and overall survival (OS). RESULTS: A total of 34 patients with relapses were recorded, and 25 of these (73.5%) were men. Twenty-five patients were treated with systemic TT: 65% of patients received TT against the vascular endothelial growth factor pathway (including sunitinib), 21.7% received mammalian target of rapamycin inhibitors and 13% received immunotherapy. The median (interquartile range) time to relapse was 20.3 (5.2-20.4) months from diagnosis, and 7.5 months (1.0-8.5) from the end of adjuvant suntinib treatment. At a median follow-up of 23.5 months, 24 of the 25 patients had progressed on first-line systemic therapy. The median PFS was 12.0 months (95% confidence interval [CI] 5.78-18.2). There were no statistical differences in PFS between different treatments or sunitinib rechallenge. PFS was not statistically different in patients relapsing on or after adjuvant suntinib treatment (≤ 6 or >6 months after adjuvant suntinib ending). The ORR was 20.5%. The median OS was 29.1 months (95% CI 16.4-41.8). CONCLUSIONS: Rechallenge with sunitinib or other systemic therapies is still a feasible therapeutic option that provides patients with advanced or metastastic RCC with additional clinical benefits with regard to PFS and OS after failed response to adjuvant sunitinib.
引用
- de Velasco G, Ruiz-Granados Á, Reig O, et al. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. BJU Int. 2021. PMID: 33547860. doi:10.1111/bju.15356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。